Skip to main content
NVDA+0.10%AAPL-0.38%GOOGL+0.64%MSFT+0.09%AMZN+0.20%TSM+1.02%SPCX-1.36%AVGO+2.97%META+0.35%TSLA-0.11%SKHY+2.46%MU+0.19%BRK-B+0.11%LLY+0.04%JPM+0.10%AMD+2.70%WMT-0.06%V-0.44%XOM+0.17%JNJ-0.09%ASMLa+1.97%INTC-0.18%MA-0.09%0700.HK+2.17%ABBV-0.02%1398.HK+0.97%CSCO-0.66%ORCL-1.98%CVX-0.97%BAC-0.77%COST+0.15%KO+0.22%DELL-3.46%CAT+1.30%LRCX+6.98%0005.HK-0.72%AMAT+6.51%PG-0.79%HSBA.L-1.61%AP2d+5.05%UNH+0.45%3988.HK+0.79%GE+0.26%1816.HK-30.07%MS-0.46%HD-0.84%0939.HK+1.23%NFLX-4.67%0857.HK-0.42%ARM+4.04%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%GBPZAR-0.24%EURZAR-0.22%USDILS+0.16%NZDMXN-0.16%USDCAD+0.16%USDNOK+0.15%CHFSGD-0.14%AUDCHF+0.14%USDCHF+0.14%AUDCAD+0.13%AUDNOK+0.13%GBPUSD-0.12%GBPSGD-0.12%EURUSD-0.11%USDJPY+0.11%GBPAUD-0.10%USDZAR-0.10%USDDKK+0.10%EURSGD-0.10%EURHKD-0.10%SGDJPY+0.10%NZDCHF+0.09%EURCNH-0.09%AUDJPY+0.09%NZDUSD-0.09%USDSEK+0.09%NZDSGD-0.08%USDTRY+0.07%EURAUD-0.07%AUDDKK+0.07%NZDCAD+0.07%USDMXN-0.07%CHFSEK-0.07%USDPLN+0.06%AUDNZD+0.06%EURNZD-0.06%EURCHF+0.06%PLNJPY+0.05%CADJPY-0.05%NZDJPY+0.05%EURNOK+0.04%EURCZK+0.04%EURPLN-0.04%NOKJPY-0.04%USDCOP-0.04%GBPCAD+0.04%GBPNZD-0.04%USDTHB-0.03%GBPCHF+0.03%EURGBP+0.03%USDCNH-0.02%EURSEK-0.02%AUDSGD-0.02%EURCAD+0.02%CHFNOK+0.01%AUDUSD-0.01%CHFJPY-0.01%GBPJPY-0.01%USDSGD+0.01%CADCHF-0.01%USDHKD+0.01%EURJPY0.00%EURDKK0.00%COTTON+2.11%W1+1.70%C1+1.23%USOIL-0.99%UKOIL-0.77%S1+0.62%XAUUSD-0.59%GAUUSD-0.59%GAGUSD-0.35%XAGUSD-0.35%XPTUSD-0.29%HG1+0.16%BTCUSD+0.42%ETHUSD+1.37%USDTUSD-0.01%XRPUSD+1.52%SOLUSD+0.79%TRXUSDT+1.08%ZECUSDT+3.38%DOGEUSD+0.98%XMRUSDT+7.71%LINKUSD+1.31%XLMUSD+1.25%UNIUSD-0.29%BCHUSDT-0.16%LTCUSD+0.17%HBARUSDT+6.66%SUIUSD+9.72%TONUSD+24.06%TAOUSDT+2.09%AAVEUSD-2.13%DOTUSDT+1.82%ICPUSDT+2.45%ONDOUSDT+2.10%ARBUSDT+4.84%WLDUSDT+4.64%JUPUSDT+6.96%ATOMUSDT+0.83%INJUSDT-2.36%STXUSDT+2.03%FETUSDT+3.28%SEIUSDT+16.26%TIAUSDT+1.02%PYTHUSDT+0.21%IMXUSDT-0.28%OPUSDT+4.06%GRTUSDT+8.83%POLUSDT+2.32%WIFUSDT-4.64%IOTAUSDT-1.78%FARTCOINUSDT+6.20%AXSUSDT-0.52%EOSUSDT+3.15%DYDXUSDT-1.80%ORDIUSDT+3.84%GALAUSDT+1.29%NOTUSDT+5.67%RONINUSDT-1.03%NVDA+0.10%AAPL-0.38%GOOGL+0.64%MSFT+0.09%AMZN+0.20%TSM+1.02%SPCX-1.36%AVGO+2.97%META+0.35%TSLA-0.11%SKHY+2.46%MU+0.19%BRK-B+0.11%LLY+0.04%JPM+0.10%AMD+2.70%WMT-0.06%V-0.44%XOM+0.17%JNJ-0.09%ASMLa+1.97%INTC-0.18%MA-0.09%0700.HK+2.17%ABBV-0.02%1398.HK+0.97%CSCO-0.66%ORCL-1.98%CVX-0.97%BAC-0.77%COST+0.15%KO+0.22%DELL-3.46%CAT+1.30%LRCX+6.98%0005.HK-0.72%AMAT+6.51%PG-0.79%HSBA.L-1.61%AP2d+5.05%UNH+0.45%3988.HK+0.79%GE+0.26%1816.HK-30.07%MS-0.46%HD-0.84%0939.HK+1.23%NFLX-4.67%0857.HK-0.42%ARM+4.04%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%GBPZAR-0.24%EURZAR-0.22%USDILS+0.16%NZDMXN-0.16%USDCAD+0.16%USDNOK+0.15%CHFSGD-0.14%AUDCHF+0.14%USDCHF+0.14%AUDCAD+0.13%AUDNOK+0.13%GBPUSD-0.12%GBPSGD-0.12%EURUSD-0.11%USDJPY+0.11%GBPAUD-0.10%USDZAR-0.10%USDDKK+0.10%EURSGD-0.10%EURHKD-0.10%SGDJPY+0.10%NZDCHF+0.09%EURCNH-0.09%AUDJPY+0.09%NZDUSD-0.09%USDSEK+0.09%NZDSGD-0.08%USDTRY+0.07%EURAUD-0.07%AUDDKK+0.07%NZDCAD+0.07%USDMXN-0.07%CHFSEK-0.07%USDPLN+0.06%AUDNZD+0.06%EURNZD-0.06%EURCHF+0.06%PLNJPY+0.05%CADJPY-0.05%NZDJPY+0.05%EURNOK+0.04%EURCZK+0.04%EURPLN-0.04%NOKJPY-0.04%USDCOP-0.04%GBPCAD+0.04%GBPNZD-0.04%USDTHB-0.03%GBPCHF+0.03%EURGBP+0.03%USDCNH-0.02%EURSEK-0.02%AUDSGD-0.02%EURCAD+0.02%CHFNOK+0.01%AUDUSD-0.01%CHFJPY-0.01%GBPJPY-0.01%USDSGD+0.01%CADCHF-0.01%USDHKD+0.01%EURJPY0.00%EURDKK0.00%COTTON+2.11%W1+1.70%C1+1.23%USOIL-0.99%UKOIL-0.77%S1+0.62%XAUUSD-0.59%GAUUSD-0.59%GAGUSD-0.35%XAGUSD-0.35%XPTUSD-0.29%HG1+0.16%BTCUSD+0.42%ETHUSD+1.37%USDTUSD-0.01%XRPUSD+1.52%SOLUSD+0.79%TRXUSDT+1.08%ZECUSDT+3.38%DOGEUSD+0.98%XMRUSDT+7.71%LINKUSD+1.31%XLMUSD+1.25%UNIUSD-0.29%BCHUSDT-0.16%LTCUSD+0.17%HBARUSDT+6.66%SUIUSD+9.72%TONUSD+24.06%TAOUSDT+2.09%AAVEUSD-2.13%DOTUSDT+1.82%ICPUSDT+2.45%ONDOUSDT+2.10%ARBUSDT+4.84%WLDUSDT+4.64%JUPUSDT+6.96%ATOMUSDT+0.83%INJUSDT-2.36%STXUSDT+2.03%FETUSDT+3.28%SEIUSDT+16.26%TIAUSDT+1.02%PYTHUSDT+0.21%IMXUSDT-0.28%OPUSDT+4.06%GRTUSDT+8.83%POLUSDT+2.32%WIFUSDT-4.64%IOTAUSDT-1.78%FARTCOINUSDT+6.20%AXSUSDT-0.52%EOSUSDT+3.15%DYDXUSDT-1.80%ORDIUSDT+3.84%GALAUSDT+1.29%NOTUSDT+5.67%RONINUSDT-1.03%
XB

Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ • Healthcare

$8.19
+$0.03 (+0.5%)
Market closed

Last close at September 18, 2026 at 20:00 UTC

Open$8.1
Day Range$7.93 - $8.25
Avg. Volume (3M)1.7M
Market Cap$1.4B
52 Week Range
$5.25$10.08
Next EarningsIn 45 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$92.1M100%
Gross Profitminus cost of goods$79.5M86%
Operating Incomeminus R&D and overhead$5.1M6%

In plain terms: out of every $100 in revenue, Xeris Biopharma Holdings, Inc. currently loses $34.

Fundamentals & Financials

Revenue (TTM)
$335.4M
Net Income (TTM)
-$17.1M
EPS (TTM)
-$0.097
ROA (TTM)
-4.17%
Current Ratio
1.45

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+100.0%Q1 2026$0.06
+465.0%Q2 2026$0.01
-1582.7%Q3 2026-$0.18
Next

Nov 5

in 45 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -1582.7%

Revenue rose 28.7% to roughly $92.1 million in Xeris Biopharma’s second fiscal quarter of 2026, based on preliminary results reported August 6, 2026, with revenue of $92.1 million in line with the $90.1 million estimate (+2.2%) and up from about $71.5 million a year ago. Gross profit was roughly $79.6 million, translating to a gross margin of about 86%, while operating income came in around $5.2 million and operating margin stood near 6%. The quarter generated operating cash flow of about $8.3 million, and the company repurchased roughly $0.2 million of stock. Consensus for the next period calls for EPS of $0.02 on revenue of $101.6 million.

View full earnings history

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. develops and commercializes specialty therapies in biotechnology, centered on endocrinology, neurology, and gastroenterology, and generated $291.8 million of revenue in FY2025. The NASDAQ-listed company, traded as XERS, builds its portfolio around proprietary formulation technologies and a focused set of marketed products.

Name
Xeris Biopharma Holdings, Inc.
CEO
John Shannon
Website
www.xerispharma.com
Industry
Healthcare
Year Founded
2005
Employees
435

Today's Snapshot

AI-generated

XERS closed slightly higher at 8.20, in line with a flat sector. Shares changed hands at roughly twice its usual level. Xeris Biopharma reported strong second-quarter revenue growth.

Trading Volume

Above 10d avg 2.1M

3.8M

vs S&P 500 Today

Moderate Outperformance

+0.41%

Updated: September 18, 2026 at 20:22 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
XERS is trading near 8.20 while short-term averages sit just below the price and some medium-term averages are slightly above, reflecting a patchwork of levels that keeps bias neutral. Momentum readings are mixed — RSI around the mid‑50s with momentum and MACD showing mild weakness — and ADX under 20 signals a lack of directional strength. Volatility is contained with a modest ATR, and on‑balance volume shows accumulation even as the classic pivot lies close to the market. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$7.57 - $8.12
    Buy
  • RSI (14)51.05
    Neutral
  • Stochastic %K (14, 3, 3)46.86
    Neutral
  • MACD Level (12, 26)-0.13
    Sell

Peers & Related Assets

CLDXCelldex Therapeutics, Inc.
$38.24-1.9%
VERAVera Therapeutics, Inc.
$34-0.8%
HRMYHarmony Biosciences Holdings, Inc.
$42.02-1.7%
BCRXBioCryst Pharmaceuticals, Inc.
$8.68-0.2%
BHVNBiohaven Ltd.
$13.62-1.9%
MAZEMaze Therapeutics, Inc.
$22.52-3.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.